ERBB2 and invasive breast carcinoma: Over a period of 2.5 years, we recruited 210 patients diagnosed with invasive breast carcinoma who were treated with standard neoadjuvant chemotherapy (NAC) protocol of 4 cycles of Anthracycline and Cyclophosphamide followed by four cycles of Docetaxel (T) or Docetaxel plus Trastuzumab for HER2+ diseases.